Overview: MPL Mutation TestIntroduction: The MPL Mutation Test detects MPL mutations to diagnose myeloproliferative disorders, causing fatigue or clotting. Aligned with 2023 ASH guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected myeloproliferative neoplasms, such as essential thrombocythemia.
Other Names: MPL Assay, Myeloproliferative Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MPL mutation testing began in the 2000s with myeloproliferative research. PCR methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects MPL mutations to diagnose myeloproliferative disorders, guides treatment, and evaluates patients with fatigue or clotting.
Test Parameters: 1. MPL Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of fatigue, clotting, or myeloproliferative symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, clotting, splenomegaly, or family history of myeloproliferative disorders. Include current medications, especially JAK inhibitors.
Consent: Written consent required, detailing the tests purpose, myeloproliferative disorder implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect MPL mutations in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for myeloproliferative disorder diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive MPL mutations confirm myeloproliferative disorder, guiding targeted therapy (e.g., ruxolitinib). Negative results may require JAK2 testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: JAK2 V617F, CALR mutation testing, or bone marrow biopsy to confirm myeloproliferative disorder diagnosis.
Test Limitations: Not all myeloproliferative disorders show MPL mutations; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH Myeloproliferative Guidelines, 2023; Blood, Tefferi A, 2022.
